ReviewFrontiers in cellular and infection microbiology2020
An Overview of Anti-Eukaryotic T6SS Effectors.
Review in Frontiers in cellular and infection microbiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 145 citations in OpenAlex.
- From gut colonization to recurrence:Gut microbes · 2026Review
- Crystal structure of the type VI secretion system adaptor protein Tla3 from Pseudomonas aeruginosa.Acta crystallographica. Section F, Structural biology communications · 2026Article
- The M91 metallopeptidase domain of the T6SS effector protein SED_RS06335 encoded in Salmonella Dublin SPI-19 exhibits antibacterial activity.BMC research notes · 2026Article
- Minor hemolysin-coregulated proteins (Hcp) form heteromeric complexes and mediate effector secretion in Bacteroidales type VI secretion systems.The Journal of biological chemistry · 2026Article
- Deciphering the pangenome of the shellfish pathogenMicrobial genomics · 2026Article
- Type VI Secretion Systems inMicroorganisms · 2026Article
- Type VI-secretion system-mediated competition and virulence in clinical and environmentalMicrobiology spectrum · 2026Article
- MoCETSE: A mixture-of-convolutional experts and transformer-based model for predicting Gram-negative bacterial secreted effectors.PLoS computational biology · 2026Article
- A type III secretion system is required for Bordetella atropi invasion of host cells in vivo.PLoS pathogens · 2026Article
- Biophysical characterization of Eag chaperones suggests the mechanism of effector transmembrane domain release.Nature communications · 2026Article
- Immune activation of primary human macrophages is suppressed by the coordinated action ofmBio · 2026Article
- T6SS1 suppresses pro-inflammatory cytokine transcription to drive immune evasion and systemic infection inInfection and immunity · 2026Article
- Structural and functional insights into Pseudomonas aeruginosa's secretion systems 1-6: regulation, role in microbial keratitis and drug targets.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026Review
- Evolutionary dynamics of type VI secretion systems in fruit fly-associatedFrontiers in microbiology · 2026Article
- The SPI-20 and SPI-21 T6SS gene clusters fromFrontiers in microbiology · 2026Article
- Type VI secretion system effectors as modulators of host immunometabolism: organelle stress, nutritional immunity, and therapeutic opportunities.Frontiers in microbiology · 2026Review
- TssW-PpkA-Fha axis controls the positioning and initiation of the type VI secretion system inmBio · 2025Article
- Genomic prediction of symbiotic interactions between two Endozoicomonas clades and their coral host, Acropora loripes.Animal microbiome · 2025Article
- Genomic profiling and experimental validation of type VI secretion system-associated proteins in Klebsiella.PLoS genetics · 2025Article
- Proteomic study of evolvedmSystems · 2025Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
The type VI secretion system (T6SS) is a transmembrane multiprotein nanomachine employed by many Gram-negative bacterial species to translocate, in a contact-dependent manner, effector proteins into adjacent prokaryotic or eukaryotic cells. Typically, the T6SS gene cluster encodes at least 13 conserved core components for the apparatus assembly and other less conserved accessory proteins and effectors. It functions as a contractile tail machine comprising a TssB/C sheath and an expelled puncturing device consisting of an Hcp tube topped by a spike complex of VgrG and PAAR proteins. Contraction of the sheath propels the tube out of the bacterial cell into a target cell and leads to the injection of toxic proteins. Different bacteria use the T6SS for specific roles according to the niche and versatility of the organism. Effectors are present both as cargo (by non-covalent interactions with one of the core components) or specialized domains (fused to structural components). Although several anti-prokaryotic effectors T6SSs have been studied, recent studies have led to a substantial increase in the number of characterized anti-eukaryotic effectors. Against eukaryotic cells, the T6SS is involved in modifying and manipulating diverse cellular processes that allows bacteria to colonize, survive and disseminate, including adhesion modification, stimulating internalization, cytoskeletal rearrangements and evasion of host innate immune responses.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.